A Potential Nanomedicine Consisting of Heparin-Loaded Polysaccharide Nanocarriers for the Treatment of Asthma

A new nanomedicine consisting of chitosan/carboxymethyl‐β‐cyclodextrin loaded with unfractioned or low‐molecular‐weight heparin is described and its potential in asthma treatment is evaluated. The nanoparticles are prepared by ionotropic gelation showing a size that between 221 and 729 nm with a positive zeta potential. The drug association efficiency is higher than 70%. Developed nanosystems are stable in Hank's balanced salt solution at pH = 6.4, releasing the drug slowly. Ex vivo assays show that nanocarriers lead to an improvement of heparin preventing mast cell degranulation. These results agree with the effective cellular internalization of the fluorescently labeled nanocarriers, and suggest these nanomedicines as promising formulations for asthma treatment. Heparin associated with nanoparticles composed of chitosan and cyclodextrins is investigated for a new application as an antiasthmatic drug. The capacity of the nanoparticles to interact with mastocytes and to prevent the degranulation of mast cells confirms the potential interest of this new nanomedicine for the treatment of asthma.